Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wesley H. Kaupinen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- -0.17
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 29.73
Financials
Revenue
$0.00-100.0%Net Income
$-24.64MEBITDA
$-21.83MFree Cash Flow
$-14.43MEPS (diluted)
$-1.70Shares Outstanding (diluted)
14.53M+1332.8%Operating Expenses
$22.73MCash & Debt
$236.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-41.72M | $-3.71 |
| 2024 | $0.00 | $-17.43M | $-7.83 |
| 2023 | $0.00 | $18.69M | $14.74 |
| 2022 | $25.90M | $-33.28M | $-29.61 |
| 2021 | $31.42M | $-45.74M | $-56.69 |
Valuation
PVLAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+650.00%Social Signal Score
Mentions (18)
- Newsseekingalpha.com·3d ago·Neutral
Palvella Therapeutics, Inc. (PVLA) Discusses QTORIN Docetaxel for Extramammary Pagets Disease Prepared Remarks Transcript Palvella Therapeutics, Inc. (PVLA) Discusses QTORIN Docetaxel for Extramammary Pagets Disease Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget's Disease (EMPD) EMPD is a serious, rare, and life-threatening genital and perianal skin cancer QTORIN™ docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment paradigm to first-line, localized topical therapy QTORIN™ docetaxel has the potential to be the first FDA-approved therapy for the estimated more than 10,000 U.S. patien
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program Third product candidate from Palvella's QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa.
View source ↗ - Newsseekingalpha.com·14d ago·Positive
Palvella Therapeutics, Inc. (PVLA) Q3 2026 Earnings Call Transcript Palvella Therapeutics, Inc. ( PVLA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Bohan Wei - Vice President of Corporate Development & New Product Planning Wesley Kaupinen - Founder, President, CEO & Director Ashley Kline Jeffrey Martini - Chief Scientific Officer Matthew Korenberg - CFO, Corporate Secretary & Treasurer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research D…
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call Palvella Therapeutics NASDAQ: PVLA is preparing for a potential U.S. launch of QTORIN rapamycin after the Food and Drug Administration accepted its application for the treatment of microcystic lymphatic malformations and granted it Priority Review.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027
View source ↗ - Newsglobenewswire.com·19d ago·Positive
…o Participate in the Stifel 2026 Healthcare Conference WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will present at the Stifel 2026 Heal…
View source ↗ - Newsglobenewswire.com·24d ago·Positive
… Corporate Update Conference Call on November 5, 2026 WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its third quarter 2026 financial results before mark…
View source ↗ - Newsmarketbeat.com·28d ago·Neutral
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session.
View source ↗ - Newsglobenewswire.com·38d ago·Positive
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
View source ↗ - Newsglobenewswire.com·40d ago·Positive
…ipate in the Chardan 10th Annual Healthcare Conference WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will participate in a fireside chat …
View source ↗ - Newsseekingalpha.com·54d ago·Neutral
…ulatory risk is now significantly reduced, with the FDA awarding a third year of OOPD funding post-positive Phase 3 results and no further efficacy studies required. PVLA's robust $250.6 million cash position supports manufacturing, regulatory, and launch efforts ahead of a targeted US commercial launch in H1 2027.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
Palvella Therapeutics Appoints James R. Treat, M.D. Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas
View source ↗ - Newsglobenewswire.com·81d ago·Positive
…rticipate in Upcoming Healthcare Investor Conferences WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, …
View source ↗ - Newsglobenewswire.com·83d ago·Negative
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.
View source ↗ - Newsseekingalpha.com·95d ago·Neutral
…l Flywheel Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform, aiming to expand QTORIN across multiple mTOR-driven dermatological indications, supporting a multi-indication commercial flywheel. Strong liquidity from a recent $230M equity raise enables PVLA to invest in commercialization and pipeline expansion, mitigating typical sm…
View source ↗ - Newsmarketbeat.com·98d ago·Negative
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
View source ↗
Earnings
Tue, Mar 30(in 4 months)
Consensus estimate $-1.95 per share
Typical surprise -19.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-1.70 vs $-1.78beat
- Tue, Aug 4$-1.52 vs $-1.17miss
- Thu, May 7$-1.20 vs $-0.90miss
- Tue, Mar 31$-1.08 vs $-0.91miss
- Tue, Nov 11$-1.03 vs $-0.85miss
- Thu, Aug 14$-0.86 vs $-0.78miss
Estimates and results for PVLA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PVLA officers and directors.
- Bought
- —
- Sold
- $13.2m
0 trades
59 trades
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
- Martini Jeffrey Ssold
41 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PVLA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
